Your browser doesn't support javascript.
loading
Chemosensitizing Activity of Histone Deacetylases Inhibitory Cyclic Hydroxamic Acids for Combination Chemotherapy of Lymphatic Leukemia.
Mishchenko, Denis V; Neganova, Margarita E; Klimanova, Elena N; Sashenkova, Tatyana E; Klochkov, Sergey G; Shevtsova, Elena F; Vystorop, Igor V; Tarasov, Vadim V; Chubarev, Vladimir N; Samsonova, Anna N; Ashraf, Ghulam Md; Barreto, George; Yarla, Nagendra Sastry; Aliev, Gjumrakch.
Afiliação
  • Mishchenko DV; Institute of Problems of Chemical Physics, Russian Academy of Sciences, Chernogolovka, 142432, Russian Federation.
  • Neganova ME; Moscow Region State University, 105005, Moscow, Russian Federation.
  • Klimanova EN; Institute of Physiologically Active Compounds, Russian Academy of Sciences, Chernogolovka, 142432, Russian Federation.
  • Sashenkova TE; Institute of Problems of Chemical Physics, Russian Academy of Sciences, Chernogolovka, 142432, Russian Federation.
  • Klochkov SG; Institute of Problems of Chemical Physics, Russian Academy of Sciences, Chernogolovka, 142432, Russian Federation.
  • Shevtsova EF; Institute of Physiologically Active Compounds, Russian Academy of Sciences, Chernogolovka, 142432, Russian Federation.
  • Vystorop IV; Institute of Physiologically Active Compounds, Russian Academy of Sciences, Chernogolovka, 142432, Russian Federation.
  • Tarasov VV; Institute of Problems of Chemical Physics, Russian Academy of Sciences, Chernogolovka, 142432, Russian Federation.
  • Chubarev VN; Institute of Pharmacy and Translational Medicine, Sechenov First Moscow State Medical University, 119991, Moscow, Russian Federation.
  • Samsonova AN; Institute of Pharmacy and Translational Medicine, Sechenov First Moscow State Medical University, 119991, Moscow, Russian Federation.
  • Ashraf GM; Institute of Physiologically Active Compounds, Russian Academy of Sciences, Chernogolovka, 142432, Russian Federation.
  • Barreto G; King Fahd Medical Research Center, King Abdulaziz University, Jeddah, Saudi Arabia.
  • Yarla NS; Departamento de Nutricion y Bioquimica, Facultad de Ciencias, Pontificia Universidad Javeriana, Bogota D.C., Colombia.
  • Aliev G; Instituto de Ciencias Biomédicas, Universidad Autónoma de Chile, Santiago, Chile.
Curr Cancer Drug Targets ; 18(4): 365-371, 2018.
Article em En | MEDLINE | ID: mdl-28669342
ABSTRACT

BACKGROUND:

Anti-tumor effect of hydroxamic acid derivatives is largely connected with its properties as efficient inhibitors of histone deacetylases, and other metalloenzymes involved in carcinogenesis.

OBJECTIVE:

The work was aimed to (i) determine the anti-tumor and chemosensitizing activity of the novel racemic spirocyclic hydroxamic acids using experimental drug sensitive leukemia P388 of mice, and (ii) determine the structure-activity relationships as metal chelating and HDAC inhibitory agents.

METHOD:

Outbreed male rat of 200-220 g weights were used in biochemical experiments. In vivo experiments were performed using the BDF1 hybrid male mice of 22-24 g weight. Lipid peroxidation, Fe (II) -chelating activity, HDAC fluorescent activity, anti-tumor and anti-metastatic activity, acute toxicity techniques were used in this study.

RESULTS:

Chemosensitizing properties of water soluble cyclic hydroxamic acids (CHA) are evaluated using in vitro activities and in vivo methods and found significant results. These compounds possess iron (II) chelating properties, and slightly inhibit lipid peroxidation. CHA prepared from triacetonamine (1a-e) are more effective Fe (II) ions cheaters, as compared to CHA prepared from 1- methylpiperidone (2a-e). The histone deacetylase (HDAC) inhibitory activity, lipophilicity and acute toxicity were influenced by the length amino acids (size) (Glycine < Alanine < Valine < Leucine < Phenylalanine). All compounds bearing spiro-N-methylpiperidine ring (2a-e) are non-toxic up to 1250 mg/kg dose, while compounds bearing spiro-tetramethylpiperidine ring (1a-e) exhibit moderate toxicity which increases with increasing lipophility, but not excite at 400 mg/kg.

CONCLUSION:

It was shown that the use of combination of non-toxic doses of cisplatin (cPt) or cyclophosphamide with CHA in most cases result in the appearance of a considerable anti-tumor effect of cytostatics. The highest chemosensitizing activity with respect to leukemia Р388 is demonstrated by the CHA derivatives of Valine 1c or 2c.
Assuntos
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Leucemia Linfoide / Protocolos de Quimioterapia Combinada Antineoplásica / Inibidores de Histona Desacetilases / Ácidos Hidroxâmicos Idioma: En Ano de publicação: 2018 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Leucemia Linfoide / Protocolos de Quimioterapia Combinada Antineoplásica / Inibidores de Histona Desacetilases / Ácidos Hidroxâmicos Idioma: En Ano de publicação: 2018 Tipo de documento: Article